1. Chromosomes and Gene Expression
Download icon

Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres

  1. Juan Manuel Povedano
  2. Paula Martinez
  3. Rosa Serrano
  4. Águeda Tejera
  5. Gonzalo Gómez-López
  6. Maria Bobadilla
  7. Juana Maria Flores
  8. Fátima Bosch
  9. Maria A Blasco  Is a corresponding author
  1. Spanish National Cancer Centre (CNIO), Spain
  2. F. Hoffmann-La Roche Ltd, Switzerland
  3. Complutense University of Madrid, Spain
  4. Autonomous University of Barcelona, Spain
Research Article
  • Cited 43
  • Views 10,162
  • Annotations
Cite this article as: eLife 2018;7:e31299 doi: 10.7554/eLife.31299

Abstract

Pulmonary fibrosis is a fatal lung disease characterized by fibrotic foci and inflammatory infiltrates. Short telomeres can impair tissue regeneration and are found both in hereditary and sporadic cases. We show here that telomerase expression using AAV9 vectors shows therapeutic effects in a mouse model of pulmonary fibrosis owing to a low-dose bleomycin insult and short telomeres. AAV9 preferentially targets regenerative alveolar type II cells (ATII). AAV9-Tert-treated mice show improved lung function and lower inflammation and fibrosis at 1-3 weeks after viral treatment, and improvement or disappearance of the fibrosis at 8 weeks after treatment. AAV9-Tert treatment leads to longer telomeres and increased proliferation of ATII cells, as well as lower DNA damage, apoptosis, and senescence. Transcriptome analysis of ATII cells confirms downregulation of fibrosis and inflammation pathways. We provide a proof-of-principle that telomerase activation may represent an effective treatment for pulmonary fibrosis provoked or associated with short telomeres.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Juan Manuel Povedano

    Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain
    Competing interests
    No competing interests declared.
  2. Paula Martinez

    Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain
    Competing interests
    No competing interests declared.
  3. Rosa Serrano

    Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain
    Competing interests
    No competing interests declared.
  4. Águeda Tejera

    Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain
    Competing interests
    No competing interests declared.
  5. Gonzalo Gómez-López

    Structural Biology and Biocomputing Program, Spanish National Cancer Centre (CNIO), Madrid, Spain
    Competing interests
    No competing interests declared.
  6. Maria Bobadilla

    Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
    Competing interests
    Maria Bobadilla, is an employee for F. Hoffmann-La Roche Ltd, and the author declares no other competing financial interests.
  7. Juana Maria Flores

    Animal Surgery and Medicine Department, Complutense University of Madrid, Madrid, Spain
    Competing interests
    No competing interests declared.
  8. Fátima Bosch

    Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  9. Maria A Blasco

    Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain
    For correspondence
    mblasco@cnio.es
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4211-233X

Funding

Ministerio de Economía y Competitividad (SAF2013-45111-R)

  • Paula Martinez

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal procedures were approved by the CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA) and conducted in accordance to the recommendations of the Federation of European Laboratory Animal Science Associations (FELASA).

Reviewing Editor

  1. Kathleen Collins, University of California, Berkeley, United States

Publication history

  1. Received: August 16, 2017
  2. Accepted: January 23, 2018
  3. Accepted Manuscript published: January 30, 2018 (version 1)
  4. Version of Record published: February 19, 2018 (version 2)

Copyright

© 2018, Povedano et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,162
    Page views
  • 1,030
    Downloads
  • 43
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics
    Natalia Petrenko, Kevin Struhl
    Research Article Updated

    The preinitiation complex (PIC) for transcriptional initiation by RNA polymerase (Pol) II is composed of general transcription factors that are highly conserved. However, analysis of ChIP-seq datasets reveals kinetic and compositional differences in the transcriptional initiation process among eukaryotic species. In yeast, Mediator associates strongly with activator proteins bound to enhancers, but it transiently associates with promoters in a form that lacks the kinase module. In contrast, in human, mouse, and fly cells, Mediator with its kinase module stably associates with promoters, but not with activator-binding sites. This suggests that yeast and metazoans differ in the nature of the dynamic bridge of Mediator between activators and Pol II and the composition of a stable inactive PIC-like entity. As in yeast, occupancies of TATA-binding protein (TBP) and TBP-associated factors (Tafs) at mammalian promoters are not strictly correlated. This suggests that within PICs, TFIID is not a monolithic entity, and multiple forms of TBP affect initiation at different classes of genes. TFIID in flies, but not yeast and mammals, interacts strongly at regions downstream of the initiation site, consistent with the importance of downstream promoter elements in that species. Lastly, Taf7 and the mammalian-specific Med26 subunit of Mediator also interact near the Pol II pause region downstream of the PIC, but only in subsets of genes and often not together. Species-specific differences in PIC structure and function are likely to affect how activators and repressors affect transcriptional activity.

    1. Chromosomes and Gene Expression
    2. Structural Biology and Molecular Biophysics
    Luka Bacic et al.
    Research Article Updated

    The chromatin remodeler ALC1 is recruited to and activated by DNA damage-induced poly(ADP-ribose) (PAR) chains deposited by PARP1/PARP2/HPF1 upon detection of DNA lesions. ALC1 has emerged as a candidate drug target for cancer therapy as its loss confers synthetic lethality in homologous recombination-deficient cells. However, structure-based drug design and molecular analysis of ALC1 have been hindered by the requirement for PARylation and the highly heterogeneous nature of this post-translational modification. Here, we reconstituted an ALC1 and PARylated nucleosome complex modified in vitro using PARP2 and HPF1. This complex was amenable to cryo-EM structure determination without cross-linking, which enabled visualization of several intermediate states of ALC1 from the recognition of the PARylated nucleosome to the tight binding and activation of the remodeler. Functional biochemical assays with PARylated nucleosomes highlight the importance of nucleosomal epitopes for productive remodeling and suggest that ALC1 preferentially slides nucleosomes away from DNA breaks.